{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T21:31:52Z","timestamp":1789939912176,"version":"4.0.1"},"reference-count":42,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.jhep.2018.01.022","type":"journal-article","created":{"date-parts":[[2018,2,8]],"date-time":"2018-02-08T03:40:23Z","timestamp":1518061223000},"page":"1163-1171","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Intra-arterial idarubicin_lipiodol without embolisation in hepatocellular carcinoma: The LIDA-B phase I trial"],"prefix":"10.1016","volume":"68","author":[{"given":"Boris","family":"Guiu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Louis","family":"Jouve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3132-7730","authenticated-orcid":false,"given":"Antonin","family":"Schmitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Minello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Bonnetain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Cassinotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauranne","family":"Piron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Cercueil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romaric","family":"Loffroy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Latournerie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma\u00ebva","family":"Wendremaire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00f4me","family":"Lepage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Boulin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2018.01.022_b0005","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.jhep.2011.12.001","article-title":"EASL-EORTC Clinical Practice Guidelines: management of hepatocellular carcinoma","volume":"56","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2018.01.022_b0010","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s00270-006-0062-3","article-title":"Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies","volume":"30","author":"Marelli","year":"2007","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.jhep.2018.01.022_b0015","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1007\/BF00687096","volume":"31","author":"Kawai","year":"1992","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.jhep.2018.01.022_b0020","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1002\/1097-0142(19941101)74:9<2449::AID-CNCR2820740910>3.0.CO;2-4","article-title":"Transcatheter arterial embolization with or without cisplatin treatment of hepatocellular carcinoma. A randomized controlled study","volume":"74","author":"Chang","year":"1994","journal-title":"Cancer"},{"key":"10.1016\/j.jhep.2018.01.022_b0025","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/S0140-6736(02)08649-X","article-title":"Arterial embolisation or chemoembolisation vs. symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomized controlled trial","volume":"359","author":"Llovet","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2018.01.022_b0030","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s00270-009-9750-0","article-title":"Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma","volume":"33","author":"Malagari","year":"2010","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.jhep.2018.01.022_b0035","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1038\/bjc.2013.85","article-title":"A randomised phase II\/III trial of 3-weekly cisplatin-based sequential transarterial chemoembolisation vs embolisation alone for hepatocellular carcinoma","volume":"108","author":"Meyer","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jhep.2018.01.022_b0040","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1200\/JCO.2015.64.0821","article-title":"Randomized trial of hepatic artery embolization for hepatocellular carcinoma using doxorubicin-eluting microspheres compared with embolization with microspheres alone","volume":"34","author":"Brown","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2018.01.022_b0045","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.ejso.2005.11.003","article-title":"Chemoocclusion vs chemoperfusion for treatment of advanced hepatocellular carcinoma: a randomized trial","volume":"32","author":"Kirchhoff","year":"2006","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.jhep.2018.01.022_b0050","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jhep.2009.09.004","article-title":"Transarterial chemotherapy alone vs. transarterial chemoembolization for hepatocellular carcinoma: a randomized phase III trial","volume":"51","author":"Okusaka","year":"2009","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2018.01.022_b0055","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s00535-010-0306-5","article-title":"A novel transcatheter arterial infusion chemotherapy using iodized oil and degradable starch microspheres for hepatocellular carcinoma: a prospective randomized trial","volume":"46","author":"Yamasaki","year":"2011","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.jhep.2018.01.022_b0060","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1093\/jnci\/djs464","article-title":"Roles played by chemolipiodolization and embolization in chemoembolization for hepatocellular carcinoma: single-blind, randomized trial","volume":"105","author":"Shi","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jhep.2018.01.022_b0065","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1002\/1097-0142(19910315)67:6<1471::AID-CNCR2820670602>3.0.CO;2-G","article-title":"Rationale for different chemotherapeutic and radiation therapy strategies in cancer management","volume":"67","author":"Looney","year":"1991","journal-title":"Cancer"},{"key":"10.1016\/j.jhep.2018.01.022_b0070","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1088\/0031-9155\/50\/1\/008","article-title":"Tumour resistance to cisplatin: a modelling approach","volume":"50","author":"Marcu","year":"2005","journal-title":"Phys Med Biol"},{"key":"10.1016\/j.jhep.2018.01.022_b0075","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.ctrv.2010.07.006","article-title":"Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization","volume":"37","author":"Raoul","year":"2011","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.jhep.2018.01.022_b0080","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1097\/CAD.0b013e328346a0c5","article-title":"Screening of anticancer drugs for chemoembolization of hepatocellular carcinoma","volume":"22","author":"Boulin","year":"2011","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.jhep.2018.01.022_b0085","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s00330-015-3855-4","article-title":"Improved stability of lipiodol-drug emulsion for transarterial chemoembolization of hepatocellular carcinoma results in improved pharmacokinetic profile: proof of concept using idarubicin","volume":"26","author":"Boulin","year":"2016","journal-title":"Eur Radiol"},{"key":"10.1016\/j.jhep.2018.01.022_b0090","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S0168-8278(01)00130-1","article-title":"Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the liver","volume":"35","author":"Bruix","year":"2001","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2018.01.022_b0095","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2307\/2531628","article-title":"Continual Reassessment Method: a practical design for phase I clinical studies in cancer","volume":"46","author":"O\u2019Quigley","year":"1990","journal-title":"Biometrics"},{"key":"10.1016\/j.jhep.2018.01.022_b0100","doi-asserted-by":"crossref","first-page":"673","DOI":"10.2307\/2532905","article-title":"Continual reassessment method: a likelihood approach","volume":"52","author":"O'Quigley","year":"1996","journal-title":"Biometrics"},{"key":"10.1016\/j.jhep.2018.01.022_b0105","unstructured":"NCI. Common Terminology Criteria for Adverse Events v4.0 (2009). https:\/\/www.eortc.be\/services\/doc\/ctc\/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf Accessed 12 February 2018."},{"key":"10.1016\/j.jhep.2018.01.022_b0110","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1007\/s00270-015-1208-y","article-title":"Treatment of liver tumors with lipiodol TACE: technical recommendations from experts opinion","volume":"39","author":"de Baere","year":"2016","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.jhep.2018.01.022_b0115","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1055\/s-0030-1247132","article-title":"Modified RECIST (mRECIST) assessment for hepatocellular carcinoma","volume":"30","author":"Lencioni","year":"2010","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jhep.2018.01.022_b0120","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jhep.2018.01.022_b0125","doi-asserted-by":"crossref","first-page":"S132","DOI":"10.1002\/(SICI)1097-0215(1999)83:12+<132::AID-IJC23>3.0.CO;2-4","article-title":"Interpreting the meaningfulness of changes in health-related quality of life scores: lessons from studies in adults","volume":"12","author":"Osoba","year":"1999","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jhep.2018.01.022_b0130","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1111\/apt.12746","article-title":"Idarubicin-loaded beads for chemoembolization of hepatocellular carcinoma: results of the IDASPHERE phase I trial","volume":"39","author":"Boulin","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2018.01.022_b0135","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00270-009-9711-7","article-title":"Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma:results of the PRECISION V study","volume":"33","author":"Lammer","year":"2010","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.jhep.2018.01.022_b0140","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/ejhf.654","article-title":"2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)","volume":"19","author":"Zamorano","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jhep.2018.01.022_b0145","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1148\/radiology.163.2.3031724","article-title":"Hepatocellular carcinoma:treatment with intraarterial iodized oil with and without chemotherapeutic agents","volume":"163","author":"Takayasu","year":"1987","journal-title":"Radiology"},{"key":"10.1016\/j.jhep.2018.01.022_b0150","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1038\/sj.bjc.6690266","article-title":"In vitro assessment of Lipiodol-targeted radiotherapy for liver and colorectal cancer cell lines","volume":"79","author":"Al-Mufti","year":"1999","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jhep.2018.01.022_b0155","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1148\/radiology.168.2.2839866","article-title":"Hepatic artery injection of I131 labeled Lipiodol. I Biodistribution study results in patients with hepatocellular carcinoma and liver metastases","volume":"168","author":"Raoul","year":"1988","journal-title":"Radiology"},{"key":"10.1016\/j.jhep.2018.01.022_b0160","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1148\/radiology.201.3.8939223","article-title":"Quantification of tumor uptake of iodized oils and emulsions of iodized oils: experimental study","volume":"201","author":"de Baere","year":"1996","journal-title":"Radiology"},{"key":"10.1016\/j.jhep.2018.01.022_b0165","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1002\/1097-0142(19920801)70:3<585::AID-CNCR2820700308>3.0.CO;2-#","article-title":"Chemoembolization of hepatocellular carcinomas. A study of the biodistribution and pharmacokinetics of doxorubicin","volume":"70","author":"Raoul","year":"1992","journal-title":"Cancer"},{"key":"10.1016\/j.jhep.2018.01.022_b0170","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1023\/A:1011186708754","article-title":"Phase I and pharmacokinetic study of hepatic arterial infusion with oxaliplatin in combination with folinic acid and 5-fluorouracil in patients with hepatic metastases from colorectal cancer","volume":"12","author":"Kern","year":"2001","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhep.2018.01.022_b0175","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.leukres.2004.07.002","article-title":"A phase I pharmacological study of idarubicin, cytarabine, etoposide, and the multidrug resistance protein (MDR1\/Pgp) inhibitor PSC-833 in patients with refractory leukemia","volume":"29","author":"Bauer","year":"2005","journal-title":"Leuk Res"},{"key":"10.1016\/j.jhep.2018.01.022_b0180","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1097\/00001813-200111000-00003","article-title":"Increased cytotoxicity and stability of Lipiodol-pirarubicin emulsion compared to classical doxorubicin-Lipiodol: potential advantage for chemoembolization of unresectable hepatocellular carcinoma","volume":"12","author":"Favoulet","year":"2001","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.jhep.2018.01.022_b0185","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/0168-8278(91)90873-A","article-title":"Pharmacokinetics and toxicity of intraarterial adriamycin for hepatocellular carcinoma: effect of coadministration of lipiodol","volume":"13","author":"Johnson","year":"1991","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2018.01.022_b0190","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/0168-8278(90)90220-L","article-title":"Intra-arterial doxorubicin and Lipiodol for inoperable hepatocellular carcinoma: a comparison with intravenous doxorubicin","volume":"11","author":"Kalayci","year":"1990","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2018.01.022_b0195","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1007\/s00330-016-4445-9","article-title":"Advanced-stage hepatocellular carcinoma with portal vein thrombosis: conventional vs. drug-eluting beads transcatheter arterial chemoembolization","volume":"27","author":"Gorodetski","year":"2017","journal-title":"Eur Radiol"},{"key":"10.1016\/j.jhep.2018.01.022_b0200","unstructured":"U.S. Department of Health and Human Services. Food and Drug Administration. Cancer Drug approval endpoints. https:\/\/www.fda.gov\/Drugs\/DevelopmentApprovalProcess\/DevelopmentResources\/CancerDrugs\/ucm094586.htm. Accessed 12 February 2018."},{"key":"10.1016\/j.jhep.2018.01.022_b0205","unstructured":"European Medicines Agency. Guideline on evaluation of anticancer medicinal products in man, 2016. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2016\/03\/WC500203320.pdf. Accessed 12 February 2018."},{"key":"10.1016\/j.jhep.2018.01.022_b0210","doi-asserted-by":"crossref","first-page":"e010696","DOI":"10.1136\/bmjopen-2015-010696","article-title":"An explorative study to assess the association between health-related quality of life and the recommended phase II dose in a phase I trial: idarubicin-loaded beads for chemoembolization of hepatocellular carcinoma","volume":"6","author":"Anota","year":"2016","journal-title":"BMJ Open"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827818300692?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827818300692?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T16:30:20Z","timestamp":1714581020000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827818300692"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":42,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["S0168827818300692"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2018.01.022","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intra-arterial idarubicin_lipiodol without embolisation in hepatocellular carcinoma: The LIDA-B phase I trial","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2018.01.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}